Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

27
DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
27
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

10.9K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.9K
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

36
Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
36
Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

9
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
9
Hemodialysis III: Nursing Management01:25

Hemodialysis III: Nursing Management

26
The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this...
26
Blood Transfusion01:15

Blood Transfusion

583
Blood transfusion is a critical medical procedure that saves lives and treats various medical conditions. It involves transferring blood from a donor to a recipient. This process requires a thorough understanding of the ABO blood group system and its associated antigens and antibodies.
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
583

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.

The New England journal of medicine·2026
Same author

IGHV mutational status and BCR stereotypy in chronic lymphocytic leukemia: A Turkish cohort analysis.

Annals of hematology·2026
Same author

Innate immunogenetic synergy between KIR and Neanderthal-derived OAS variants predicts COVID-19 outcomes.

PloS one·2026
Same author

Response to the comment on "[11C]-Methionine PET/CT in evaluation of bone marrow infiltration and usage as a prognostic tool in multiple myeloma".

Annals of nuclear medicine·2026
Same author

Antenatal management of fetal and neonatal alloimmune thrombocytopenia: Integration of clinical history and maternal HLA-DRB3*01:01 genotyping in clinical decision-making.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2026
Same author

Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma: A Multicenter Real-World Experience

Turkish journal of haematology : official journal of Turkish Society of Haematology·2026

Related Experiment Video

Updated: Jul 13, 2025

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases
05:57

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases

Published on: August 2, 2022

4.1K

The world apheresis association registry, 2023 update.

Hans Vrielink1, Kaatje Le Poole1, Bernd Stegmayr2

  • 1Unit of Transfusion medicine of Sanquin Blood Supply, Sanquin Blood Supply Foundation in Amsterdam, the Netherlands.

Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis
|October 12, 2023
PubMed
Summary

The WAA apheresis registry reports on over 58,000 procedures across 27 centers, showing diverse therapeutic apheresis (TA) uses, primarily stem cell collection for multiple myeloma. Adverse events were infrequent, with most being mild to moderate.

Keywords:
Adverse eventsApheresisIndicationsProceduresRegister

More Related Videos

Biobanking of Human Aqueous and Vitreous Liquid Biopsies for Molecular Analyses
14:54

Biobanking of Human Aqueous and Vitreous Liquid Biopsies for Molecular Analyses

Published on: September 11, 2023

2.4K
Expansion and Enrichment of Gamma-Delta γδ T Cells from Apheresed Human Product
11:51

Expansion and Enrichment of Gamma-Delta γδ T Cells from Apheresed Human Product

Published on: September 22, 2021

9.0K

Related Experiment Videos

Last Updated: Jul 13, 2025

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases
05:57

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases

Published on: August 2, 2022

4.1K
Biobanking of Human Aqueous and Vitreous Liquid Biopsies for Molecular Analyses
14:54

Biobanking of Human Aqueous and Vitreous Liquid Biopsies for Molecular Analyses

Published on: September 11, 2023

2.4K
Expansion and Enrichment of Gamma-Delta γδ T Cells from Apheresed Human Product
11:51

Expansion and Enrichment of Gamma-Delta γδ T Cells from Apheresed Human Product

Published on: September 22, 2021

9.0K

Area of Science:

  • Hematology
  • Nephrology
  • Oncology

Background:

  • The World Apheresis Association (WAA) registry collects global data on apheresis procedures.
  • Apheresis is a critical therapeutic option for various medical conditions.

Purpose of the Study:

  • To provide an updated overview of apheresis indications, procedure types, and adverse events (AEs) from the WAA registry.
  • To analyze trends in therapeutic apheresis (TA) from 2018-2022.

Main Methods:

  • Data from 27 centers within the WAA registry, covering 9,500 patients and 58,355 apheresis procedures (2018-2022).
  • Analysis of procedure types, diagnoses, vascular access, anticoagulants, and reported adverse events.

Main Results:

  • Stem cell collection was the most common procedure (51% for multiple myeloma).
  • Plasma exchange (PEX) constituted 28% of procedures, with TTP as the main indication.
  • Adverse events occurred in 2.7% of procedures, predominantly mild (1%) or moderate (1.5%).

Conclusions:

  • Apheresis procedures exhibit a broad range of indications and procedural variations.
  • The WAA registry data indicate a low frequency of adverse events associated with therapeutic apheresis.